NEW YORK, July 8, 2016 /PRNewswire/ --
The Biotechnology industry continues to struggle with health
care costs and political issues, but some companies continue to
impress. Stock-Callers.com takes a look at today's lineup and
reviews their performances in the last few trading sessions:
Grifols S.A. (NASDAQ: GRFS), Achillion Pharmaceuticals Inc.
(NASDAQ: ACHN), Agios Pharmaceuticals Inc. (NASDAQ: AGIO), and Puma
Biotechnology Inc. (NYSE: PBYI). Learn more about these stocks and
receive your complimentary notes at:
http://stock-callers.com/registration
To access Stock-Callers.com full Notes for
free, please visit the links below.
============
Full Links to Notes
(You may have to copy and paste the links into your browser)
GRFS
Notes: http://stock-callers.com/registration/?symbol=GRFS
ACHN
Notes: http://stock-callers.com/registration/?symbol=ACHN
AGIO
Notes: http://stock-callers.com/registration/?symbol=AGIO
PBYI
Notes: http://stock-callers.com/registration/?symbol=PBYI
============
Barcelona, Spain headquartered
specialty biopharmaceutical company, Grifols S.A.'s shares gained
0.67%, closing Thursday's trading session at $16.65. The stock recorded a trading volume of
387,597 shares. Shares of the Company have advanced 7.74% in the
previous three months and 3.75% since the start of this year. The
stock is trading 5.62% above its 50-day moving average and 5.71%
above its 200-day moving average. Additionally, shares of Grifols,
which develops, manufactures, and distributes a range of plasma
derivative products primarily in the European Union, Spain, the U.S., Canada, and globally, have a Relative Strength
Index (RSI) of 58.62.
On Thursday, shares in New Haven,
Connecticut headquartered biopharmaceutical company,
Achillion Pharmaceuticals Inc., recorded a trading volume of 1.96
million shares, which was above their three months average volume
of 1.37 million shares. The stock edged 8.69% higher, ending the
day at $8.88. The Company's shares
have advanced 10.31% in the previous three months. The stock is
trading above its 50-day and 200-day moving averages by 3.05% and
6.74%, respectively. Furthermore, shares of Achillion
Pharmaceuticals, which discovers, develops, and commercializes
small molecule drug therapies for infectious diseases and immune
system disorders in the U.S. and globally, have an RSI of
56.11.
Cambridge, Massachusetts-based
biopharmaceutical company, Agios Pharmaceuticals Inc.'s stock
finished the day 0.93% lower at $42.63 and with a total volume of 441,846 shares
traded. Shares of the Company, which engages in the discovery and
development of medicines for the treatment of cancer and rare
genetic metabolic disorders in the U.S., are trading below their
50-day moving average by 13.58%. The stock has an RSI of 42.18.
Shares in Los Angeles, California
headquartered development stage biopharmaceutical company, Puma
Biotechnology Inc., ended yesterday's session 5.55% higher at
$32.15. The stock recorded a trading
volume of 479,216 shares. The Company's shares have advanced 4.21%
in the previous three months and are trading 3.42% above their
50-day moving average. Moreover, shares in Puma Biotechnology,
which focuses on the development and commercialization of products
for the treatment of various forms of cancer, have an RSI of
54.33.
--
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored
reports, articles, stock market blogs, and popular investment
newsletters covering equities listed on NYSE and NASDAQ and
micro-cap stocks. SC has two distinct and independent departments.
One department produces non-sponsored analyst certified content
generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces
sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment
newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
SC has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer") represented by a
credentialed financial analyst [for further information on analyst
credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the
"Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as
necessary, based on publicly available information which is
believed to be reliable. Content is researched, written and
reviewed on a reasonable-effort basis. The Reviewer has not
performed any independent investigations or forensic audits to
validate the information herein. The Reviewer has only
independently reviewed the information provided by the Author
according to the procedures outlined by SC. SC is not entitled to
veto or interfere in the application of such procedures by the
third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content
outside of this document has no association with the Author or the
Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any
error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is
accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. SC, the Author, and the
Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, SC, the Author, and the Reviewer do not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither SC nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly.
If you're a company we are
covering and wish to no longer feature on our coverage list contact
us via email and/or phone between 09:30 EDT
to 16:00 EDT from Monday to Friday at:
Email: info@stock-callers.com
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street,
Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Chelmsford Park SA